Why VTV Therapeutics’ stock added over 48% to its price before trading hours today

VTV Therapeutics’ (VTVT) stock price added over 48% before trading hours today.
The news that some believe is behind investors’ enthusiasm is the firm’s announcement that it will deliver two presentations at the 11th clinical trials on Alzheimer’s Disease (CTAD) Conference in Barcelona, Spain. The oral VTV Therapeutics’ (VTVT) presentations are scheduled for October 24-27, 2018.

VTV Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of oral treatments for Alzheimer disease and diabetes.

The presentations of results from the firm’s Azeliragon

This content is for paid subscribers.
Please click here to subscribe or here to log in.